Firefly Gene Illuminates Ability of Optimized CRISPR-Cpf1 to Efficiently Edit Human Genome – Scicasts (press release) (blog)
Scicasts (press release) (blog) |
Firefly Gene Illuminates Ability of Optimized CRISPR–Cpf1 to Efficiently Edit Human Genome
Scicasts (press release) (blog) Professor Michael Farzan, co-chair of TSRI’s Department of Immunology and Microbiology, and TSRI Research Associate Guocai Zhong improved the efficiency of the CRISPR–Cpf1 gene editing system by incorporating guide RNAs with “multiplexing” … |
STAT |
Bluebird Bio’s gene therapy for blood disorders yields some impressive results ― but also raises questions
STAT he field of gene therapy is making significant strides towards the day when a one-time treatment ― inserting a healthy gene into patients ― could cure a host of inherited, often fatal diseases. But it’s been a rocky road 1. And new clinical data … Drug Product in Patients with Transfusion-Dependent β-Thalassemia (TDT) and Severe Sickle Cell Disease (SCD) at …Business Wire (press release) bluebird bio (BLUE) Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobinTM Drug Product …StreetInsider.com |
Xconomy |
Bluebird Reports Early Results From Upgraded Gene Therapy
Xconomy One of the year’s most closely watched clinical studies could lead to a landmark approval of a gene therapy and throw wide open the debate over how to pay for expensive drugs. The first drips of data have emerged. Bluebird Bio (NASDAQ: BLUE) says the … Bluebird Bio’s gene therapy for blood disorders yields some …STAT Early Data for bluebird bio Gene–Therapy Candidate Show Some PromiseGenetic Engineering & Biotechnology News Bluebird Bio rebuilds case for blood disorder gene therapyFierceBiotech Endpoints News –Business Wire (press release) all 10 news articles » |